福建平潭综合实验区2013—2015年甲状腺癌发病调查分析

doi:10.11904/j.issn.1002-3070.2020.03.001

实用肿瘤学杂志 ›› 2020, Vol. 34 ›› Issue (3): 193-197.doi: 10.11904/j.issn.1002-3070.2020.03.001

• 流行病学研究 • 下一篇

福建平潭综合实验区2013—2015年甲状腺癌发病调查分析

周衍¹, 高仁生², 姚锡宇¹, 马晶昱¹, 林永添¹, 相智声¹, 江惠娟¹

1.福建省肿瘤医院,福建医科大学附属肿瘤医院(福州 350014);
2.平潭综合实验区疾病预防控制中心

收稿日期:2020-03-23 修回日期:2020-04-17 发布日期:2020-06-30
通讯作者: 周衍,E-mail:316167389qq.com
作者简介:周衍,男,(1979-),硕士,副主任医师,从事肿瘤流行病学的研究
基金资助:
福建省自然科学基金(编号:2017J01262)

Investigation and analysis of thyroid cancer incidence in Pingtan comprehensive experimental area of Fujian province,2013—2015

ZHOU Yan¹,GAO Rensheng²,YAO Xiyu¹,MA Jingyu¹,LIN Yongtian¹,XIANG Zhisheng¹,JIANG Huijuan¹

1.Fujian Provincial Cancer Hospital,The Affiliated Cancer Hospital of Fujian Medical University,Fuzhou 350014,China;
2.Disease Control and Prevention Center of Pingtan Comprehensive Experimental Area

Received:2020-03-23 Revised:2020-04-17 Published:2020-06-30

摘要/Abstract

摘要： 目的调查核实平潭综合实验区甲状腺癌是否高发,并分析其发病特征。方法选择福建省肿瘤发病报告系统中发病日期为2013—2015年的平潭户籍甲状腺癌病例;通过查阅医院病历资料核实基本信息和诊断信息,随访排除非户籍病例。计算粗发病率、标化率、累积率,分析甲状腺癌在不同性别、年龄发病情况,及不同病理类型和不同大小肿瘤的构成。中国人口标化率根据2000年中国标准人口构成计算,世界人口标化率按Segi′s世界人口构成计算。结果 2013—2015年平潭综合实验区甲状腺癌新发病例共881例;其中男性205例,女性676例。甲状腺癌粗发病率为69.30/10万,中标率为65.27/10万;男性粗发病率及中标率分别为31.78/10万和29.87/10万;女性粗发病率及中标率分别为107.95/10万和101.19/10万;女性发病是男性的3.18倍。男、女性中位发病年龄分别为46岁和47岁。男性在40-年龄组达到发病高峰,女性在45-年龄组和55-年龄组形成两个发病高峰。乳头状癌、滤泡状癌、髓样癌及其他病理类型占比分别为96.52%、1.80%、0.60%和1.08%。肿瘤最大径≤10 mm的微小癌占77.29%。结论平潭综合实验区甲状腺癌发病高于同期福建省及全国平均水平,以乳头状癌为主,微小癌占比较高。

关键词: 甲状腺癌, 发病率, 平潭综合实验区

Abstract: Objective The Objectives of this study were to investigate whether the incidence of thyroid cancer is high in Pingtan comprehensive experimental area,and analyze its incidence characteristics.Methods Thyroid cancer cases with the onset date from 2013 to 2015 in Pingtan were extacted from The Fujian Cancer Incidence Reporting.The basic information and diagnostic information were verified by examining the medical records of the hospital,and non-registered cases were excluded from follow-up.The crude incidence,standard rate and cumulative rate were calculated;the incidence of thyroid cancer in different genders and ages were analyzed;the composition of different pathological types and tumors of different sizes were compared.The standardization rate of China′s population was calculated according to the standard population composition of China in 2000 and the standardization rate of the world population was calculated according to the world population composition of Segi′s.Results From 2013 to 2015,there were 881 new cases of thyroid cancer in Pingtan comprehensive experimental area;They were 205 male and 676 female.The crude incidence of thyroid cancer was 69.30/100 000 and the age-standardized rate was 65.27/100 000 by Chinese standard population;the crude incidence and age-standardized rate of males were 31.78/100 000 and 29.87/100 000,respectively;107.95/100 000 and 101.19/100 000 for female;the incidence of females was 3.18 times than that of males.The median age of onset in men and women was 46 and 47 years old,respectively.Males reached the peak of incidence in the 40-age group,and females form two peaks in the 45-age group and the 55-age group.Papillary carcinoma,follicular carcinoma,medullary carcinoma and others pathological types accounted for 96.52%,1.80%,0.60% and 1.08%,respectively.Microcarcinomas with the largest diameter ≤10 mm accounted for 77.29%.Conclusion The incidence of thyroid cancer in Pingtan comprehensive experimental area is higher than the average levels of Fujian province and the nation.Papillary carcinoma is the main type,and the proportion of microcarcinoma is relatively high.

Key words: Thyroid cancer, Incidence, Pingtan comprehensive experimental area

中图分类号:

R736.1

周衍, 高仁生, 姚锡宇, 马晶昱, 林永添, 相智声, 江惠娟. 福建平潭综合实验区2013—2015年甲状腺癌发病调查分析[J]. 实用肿瘤学杂志, 2020, 34(3): 193-197.

ZHOU Yan,GAO Rensheng,YAO Xiyu,MA Jingyu,LIN Yongtian,XIANG Zhisheng,JIANG Huijuan. Investigation and analysis of thyroid cancer incidence in Pingtan comprehensive experimental area of Fujian province,2013—2015[J]. Journal of Practical Oncology, 2020, 34(3): 193-197.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.03.001

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I3/193

参考文献

1 Global Burden of Disease Cancer Collaboration,Fitzmaurice C,Akinyemiju TF,et al.Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to 2016:a systematic analysis for the Global Burden of Disease Study[J].JAMA Oncol,2018,4(11):1553-1568.
2 中国癌症中心.中国肿瘤登记工作指导手册(2016)[M].北京:人民卫生出版社,2016:59-75.
3 周衍,肖景榕,江惠娟,等.2012年福建省肿瘤登记地区恶性肿瘤发病和死亡分析[J].实用肿瘤学杂志,2016,30(4):304-308.
4 陈万青,孙可欣,郑荣寿,等.2014年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤,2018,27(1):1-14.
5 冯莉莉,杨琛,孙乔,等.2010—2014年上海市浦东新区甲状腺癌发病情况分析[J].上海预防医学,2018,30(7):574-578.
6 杨金华.浙江省嘉善县1987—2016 年甲状腺癌的发病趋势及病理分析[J].中国肿瘤,2017,26(10):769-773.
7 Derwahl M,Nicula D.Estrogen and its role in thyroid cancer[J].Endocr Relat Cancer,2014,21(5):273-283.
8 周峰,吴春晓,郑莹,等.1981—2010年上海市市区甲状腺癌的发病趋势[J].环境与职业医学,2015,32(11):997-1002.
9 Ahn HS,Kim HJ,Welch HG.Korea′s thyroid-cancer “epidemic”-screening and overdiagnosis[J].N Engl J Med,2014,371(19):1765-1767.
10 Davies L,Welch HG.Current thyroid cancer trends in the United States[J].JAMA　Otolaryngol　Head Neck Surg,2014,140(4):317-322.
11 Esserman LJ,Thompson IM,Reid B,et al.Addressing overdiagnosis and overtreatment in cancer:a prescription for change[J].Lancet Oncol,2014,15(6):234-242.
12 La Vecchia C,Malvezzi M,Bosetti C,et al.Thyroid cancer mortality andincidence:a global overview[J].Int J Cancer,2015,136(9):2187-2195.
13 James BC,Aschebrook-Kilfoy B,White MG,et al.Quality of life in thyroid cancer-assessment of physician perceptions[J].J Surg Res,2018,6(226):94-99.
14 US Preventive Services Task Force,Bibbins-Domingo K,Grossman DC,et al.Screening for thyroid cancer:US Preventive Services Task Force Recommendation Statement[J].JAMA,2017,317(18):1882-1887.
15 Haugen BR,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133.

[1]	孙坤, 王冲, 沈成凤, 张爽, 张辉, 宋桂德, 王卓, 王德征. 2015年天津市恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2020, 34(2): 114-119.
[2]	刘光霞, 赵连春, 陈芳, 贾乾, 高伟, 侯瞻, 卢亚敏. ZCCHC12对甲状腺细胞恶性转化的影响与作用机制[J]. 实用肿瘤学杂志, 2020, 34(2): 133-138.
[3]	吴丹, 王路, 王兴华, 崔亚利. ¹³¹I联合甲磺酸阿帕替尼对难治性甲状腺癌细胞的抑制作用及机制研究[J]. 实用肿瘤学杂志, 2020, 34(2): 139-143.
[4]	周家琛, 郑荣寿, 庄贵华, 张思维, 曾红梅, 陈茹, 王少明, 孙可欣, 邹小农, 魏文强, 赫捷. 2000—2015年中国肿瘤登记地区胃癌发病趋势及年龄变化[J]. 实用肿瘤学杂志, 2020, 34(1): 1-5.
[5]	戴丹, 贾尚春, 陈叶纪, 贺琴, 查震球, 刘志荣. 安徽省肿瘤登记地区2015年胃癌发病与死亡[J]. 实用肿瘤学杂志, 2020, 34(1): 6-10.
[6]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[7]	朱晓云, 张亚宁, 林菲, 马碧萍. 上海市金山区2002-2013年肺癌发病及死亡分析[J]. 实用肿瘤学杂志, 2018, 32(5): 437-441.
[8]	孔繁巍综述, 赵长久审校. 分化型甲状腺癌碘131治疗后的外周血细胞改变[J]. 实用肿瘤学杂志, 2018, 32(5): 476-479.
[9]	教玉颖综述, 付鹏审校. 甲状腺癌与干扰素-γ、白介素-6关系的研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 88-92.
[10]	周衍,肖景榕,江惠娟,林永添,马晶昱. 2012年福建省肿瘤登记地区恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2016, 30(4): 304-308.
[11]	程卫,赵华. 重组人促甲状腺激素辅助¹³¹I在儿童和青少年分化型甲状腺癌的临床研究[J]. 实用肿瘤学杂志, 2016, 30(4): 309-313.
[12]	冯卓颖, 鹿瑶, 苏雁欣, 都杨. Logistic回归模型在超声评价甲状腺结节良恶性及淋巴转移的应用研究[J]. 实用肿瘤学杂志, 2015, 29(5): 385-389.
[13]	丁兆明, 陈琢, 陈丽丽. 心理社会危险因素与甲状腺癌的相关性研究[J]. 实用肿瘤学杂志, 2015, 29(5): 414-419.
[14]	孙冀, 苗素生, 裴荣综述, 毛雄辉审校. RET基因在肿瘤中的研究现状和展望[J]. 实用肿瘤学杂志, 2015, 29(5): 467-470.
[15]	王迪¹, 何月涵², 王兴华¹, 于红波¹, 王玉君¹, 崔亚利¹. 青少年分化型甲状腺癌¹³¹I治疗的临床观察[J]. 实用肿瘤学杂志, 2015, 29(3): 193-196.

福建平潭综合实验区2013—2015年甲状腺癌发病调查分析

Investigation and analysis of thyroid cancer incidence in Pingtan comprehensive experimental area of Fujian province,2013—2015

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价